Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intravenous PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease

NCT01155362 is registered in ClinicalTrials.gov with Celularity Incorporated as lead sponsor.

NCT NCT01155362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01155362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intravenous PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Lead sponsor
Celularity Incorporated
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2010
Completion date
April 30, 2014
Enrollment
50 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease